'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Bafna Pharmaceuticals Limited
BAFNAPH (NSE) · BAFNAPH (BSE 532989) · ISIN INE878I01022 · Pharmaceuticals · Est. 1995 · listed 2020 · website
ESM Stage 2 · NSE ESM Stage 2 · BSE
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹26.58 cr and profit after tax ₹0.08 cr. Revenue was 23.2% lower than in Q1 FY26.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹26.58 cr | ₹0.08 cr | 0.03 | 11 Aug 2026 |
| Q4 FY26 standalone | ₹42.24 cr | ₹2.75 cr | 1.16 | 29 May 2026 |
| Q3 FY26 standalone | ₹38.29 cr | ₹1.84 cr | 0.78 | 11 Feb 2026 |
| Q2 FY26 standalone | ₹35.47 cr | ₹3.12 cr | 1.32 | 11 Nov 2025 |
| Q1 FY26 standalone | ₹34.62 cr | ₹3.39 cr | 1.43 | 12 Aug 2025 |
| Q4 FY25 standalone | ₹39.06 cr | ₹1.31 cr | 0.55 | 26 May 2025 |
| Q3 FY25 standalone | ₹106.8 cr | ₹2.84 cr | 1.20 | 7 Feb 2025 |
| Q2 FY25 standalone | ₹73.61 cr | ₹1.89 cr | 0.80 | 12 Nov 2024 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹96.15 cr | ₹37.43 cr | ₹175.53 cr |
| 30 Sep 2025 standalone | ₹91.23 cr | ₹32.4 cr | ₹160.68 cr |
| 31 Mar 2025 standalone | ₹84.81 cr | ₹28.2 cr | ₹153.08 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 75.00% | 9.34% | 0.00% | 25.00% |
Latest filings
- Annual Report FY2025-26 (New) 19 August 2026 · NSE
- Annual Report FY2025-26 (New) 19 August 2026 · BSE
- We herewith enclose the Unaudited Financial Results for the Quarter ended June 30, 2026 as approved by the Board of Directors in its meeting held on August 11, 2026. 11 August 2026 · BSE
- Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 11, 2026. 11 August 2026 · NSE
- Bafna Pharmaceuticals Limited has submitted to the Exchange, the outcome of the Board Meeting held on 11/08/2026 along with the unaudited financial results for the quarter ended June 30, 2026. 11 August 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Ajanta Pharma Limited
- Alivus Life Sciences Limited
- Wockhardt Limited
- Morepen Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 30 September 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.